专利检索 ap:("NATIONAL INSTITUTES FOR QUANTUM SCIENCE AND TECHNOLOGY" OR "Eisai R&D Management Co., Ltd." OR "Ono Pharmaceutical Co., Ltd." OR "TAKEDA PHARMACEUTICAL COMPANY LIMITED") AND inv:"Meiei Cho" 第 1 页

1.

发明公开
NOVEL COMPOUND, a-SYNUCLEIN AGGREGATE BINDER, AND USE THEREOF 审中-公开

公开(公告)号：US20230399323A1

公开(公告)日：2023-12-14

申请号：US18022800

申请日：2021-08-24

申请人： NATIONAL INSTITUTES FOR QUANTUM SCIENCE AND TECHNOLOGY , Eisai R&D Management Co., Ltd. , Ono Pharmaceutical Co., Ltd. , TAKEDA PHARMACEUTICAL COMPANY LIMITED

发明人： Makoto Higuchi , Maiko Ono , Meiei Cho , Takeshi Yamamoto , Takeshi Wakabayashi

IPC分类号： C07D417/06 , A61K51/04 , A61K49/00

CPC分类号： C07D417/06 , A61K51/0459 , A61K49/0021

摘要： An embodiment of the present invention relates to a compound represented by formula (I) or (II), a pharmaceutically acceptable salt thereof, or a solvate thereof.

2.

发明申请
METHOD FOR PRODUCING RADIOPHARMACEUTICAL AND RADIOPHARMACEUTICAL 有权

公开(公告)号：US20220175973A1

公开(公告)日：2022-06-09

申请号：US17598400

申请日：2020-02-14

申请人： National Institutes for Quantum Science and Technology

发明人： Yukie Yoshii , Meiei Cho , Kazunori Kawamura , Hisashi Suzuki , Hiroki Hashimoto

IPC分类号： A61K51/04 , A61K47/10 , A61K47/20 , A61K47/22 , A61K47/26

摘要： A method for producing a radiopharmaceutical, the method capable of maintaining a radioactive compound retaining a chemical structure and radioactivity at the time of production and after the production, and maintaining a usable period of a radiopharmaceutical; and a radiopharmaceutical are provided. The method for producing a radiopharmaceutical that has a radioactive component containing a radioactive dithiosemicarbazone copper complex includes: a stabilization step of adding a stabilizing agent containing at least one compound selected from the group consisting of ascorbic acid, methionine, sodium ascorbate, mannitol, and butylhydroxyanisole to a solution containing the radioactive component; and a filtration step of filtering the solution containing the radioactive component or a precursor thereof with a sterilization filter. In the radiopharmaceutical, a concentration of the radioactive component is 200 MBq/mL or more in terms of radioactivity concentrations.

3.

发明申请
[11C] AND [18F] LABELED 1,3-DIPHENYL-5-(PYRIMIDIN-2-YL)-PYRIDIN-2(1H)-ONE DERIVATIVES AND THEIR USE FOR PET IMAGING OF THE AMPA RECEPTOR 审中-公开
标题翻译： [11C]和[18F]标记的1,3-二苯基-5-（吡咯烷-2-基） - 吡啶-2（1H） - 酮衍生物及其用于PETA摄取的PET成像的用途

公开(公告)号：US20160045625A1

公开(公告)日：2016-02-18

申请号：US14780665

申请日：2014-04-02

申请人： EISAI R&D MANAGEMENT CO., LTD. , NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES

发明人： Norihito Oi , Noboru Yamamoto , Michiyuki Suzuki , Yosuke Nakatani , Tetsuya Suhara , Meiei Cho , Toshimitsu Fukumura , Makoto Higuchi , Takafumi Minamimoto , Jun Maeda , Masaki Tokunaga , Yuji Nagai

IPC分类号： A61K51/04 , C07D401/04

CPC分类号： A61K51/0459 , C07D401/04

摘要： A compound selected from the group consisting of compounds represented by the formulas below or pharmaceutically acceptable salt thereof is useful in PET imaging for AMPA receptor.

摘要翻译： 选自由下式表示的化合物或其药学上可接受的盐的化合物可用于AMPA受体的PET成像。